Turn off MathJax
Article Contents
Article Navigation >  Journal of Kunming Medical University  > 2026  > Corrected proof
Zehua HAN, Xiaoyan YANG, Lian LI, Yuliang CHEN, Ai YANG, Xuelin LI, Yingying XIANG. Application and Mechanism of Endolysins in Bacteriophages[J]. Journal of Kunming Medical University.
Citation: Zehua HAN, Xiaoyan YANG, Lian LI, Yuliang CHEN, Ai YANG, Xuelin LI, Yingying XIANG. Application and Mechanism of Endolysins in Bacteriophages[J]. Journal of Kunming Medical University.
shu

Application and Mechanism of Endolysins in Bacteriophages

  • 1.

    Department of Stomatology

  • 2.

    Department of Dermatology，Yan’an Hospital Affiliated to Kunming Medical University，Kunming Yunnan 650031

  • 3.

    Department of Stomatology，No.1 Health Center，Yunnan Provincial Bureau of Institutional Affairs Management，Kunming Yunnan 650100，China

More Information
  • Corresponding author: 向盈盈，博士，昆明医科大学附属延安医院口腔科行政副主任，主任医师，教授，硕士研究生导师。长期从事3D数字化精准口腔种植技术、CAD/CAM制作全瓷冠、嵌体及各类牙体缺损、牙列缺损、牙列缺失等疑难复杂病例治疗，开展噬菌体疗法在口腔临床医学中的应用研究。担任中国医药教育协会肿瘤内照射专委会委员，中华口腔医学会全科口腔医学专委会青年委员，中华口腔医学会口腔修复学专委会青年委员，云南省口腔医学会生物医学专委会副主任委员，云南省口腔医学会修复专委会常务委员，云南女医师协会口腔分会常务委员、秘书，云南省医师协会《口腔医师分会》委员，云南省高层次卫生健康技术人才医学学科带头人，昆明市春城计划青年拔尖人才，昆明市卫生科技人才培养百工程带头人，专家工作站2个，开展新技术8项。主持1项国家自然科学基金，3项省级项目，获云南省科技进步奖三等奖1项，云南省卫生科技成果奖三等奖4项，获授权发明专利6项、实用新型专利24项。以第一作者及通讯作者发表学术论文25篇，其中SCI论文11篇，在Microbial Pathogenesis发表系列文章3篇，组织工程TOP期刊发表论文1篇，是国际上首次系统地开展难治性根尖周炎噬菌体治疗的应用研究。
  • Received Date: 2026-03-17
    Available Online: 2026-06-04
    Abstract
  • The continued spread of bacterial antibiotic resistance has become a major challenge in global public health. Endolysins derived from bacteriophages, with their unique antimicrobial mechanisms, are gradually emerging as novel antibacterial agents to replace conventional antibiotics. Endolysins are peptidoglycan hydrolases encoded by bacteriophages that exert bactericidal effects by lysing bacterial cell walls, with advantages such as strong host specificity, low propensity for resistance development, minimal disruption to the microbiota, and synergistic multi-target mechanisms . Endolysins have demonstrated potent lytic activity against various antibiotic-resistant bacteria in human medicine, veterinary medicine, and the food industry. When combined with conventional antibiotics, endolysins can produce synergistic effects, significantly reducing the minimum inhibitory concentration of antibiotics and improving survival rates in infection models. This review summarizes the application and mechanisms of action of endolysins as novel antimicrobial agents, with the aim of providing reference for future research on the application of bacteriophage endolysins in treating bacterial antibiotic-resistant infections.
    • FullText(HTML)
  • loading
    • References(79)
  • [1]
    周路路, 曹荷清, 欧维正, 等. 贵阳市2018—2021年83株临床分离非结核分枝杆菌的菌种分布及流行情况[J]. 贵州医科大学学报, 2024, 49(10): 1464-1470. doi: 10.19367/j.cnki.2096-8388.2024.10.008
    [2]
    王佳妮, 周殿友, 武丽娟. 肠道菌群在类风湿关节炎研究中的应用进展[J]. 河北医科大学学报, 2025, 46(2): 235-240.
    [3]
    Yang Y S, Wei W, Hu X X, et al. Evolution and antibacterial evaluation of 8-hydroxy-cycloberberine derivatives as a novel family of antibacterial agents against MRSA[J]. Molecules, 2019, 24(5): 984. doi: 10.3390/molecules24050984
    [4]
    Fair R J, Tor Y. Antibiotics and bacterial resistance in the 21st century[J]. Perspect Medicin Chem, 2014, 6: 25-64. doi: 10.4137/pmc.s14459
    [5]
    Bartlett J G, Gilbert D N, Spellberg B. Seven ways to preserve the miracle of antibiotics[J]. Clin Infect Dis, 2013, 56(10): 1445-1450. doi: 10.1093/cid/cit070
    [6]
    《Nature》编辑部. The antibiotic alarm[J]. Nature, 2013, 495(7440): 141.
    [7]
    Solomon S L, Oliver K B. Antibiotic resistance threats in the United States: Stepping back from the brink[J]. Am Fam Physician, 2014, 89(12): 938-941.
    [8]
    Luyt C E, Bréchot N, Trouillet J L, et al. Antibiotic stewardship in the intensive care unit[J]. Crit Care, 2014, 18(5): 480. doi: 10.1186/s13054-014-0480-6
    [9]
    彭秀玲, 邵瑞瑞, 田艳, 等. 肺炎克雷伯菌裂解性噬菌体KP-ZS5的分离及鉴定[J]. 贵州医科大学学报, 2023, 48(3): 259-265. doi: 10.19367/j.cnki.2096-8388.2023.03.002
    [10]
    韩泽华, 杨小燕, 陈昱良, 等. 噬菌体在龋病防治中的研究进展[J]. 昆明医科大学学报, 2026, 47(1): 140-147.
    [11]
    Sulakvelidze A, Alavidze Z, Morris J G Jr. Bacteriophage therapy[J]. Antimicrob Agents Chemother, 2001, 45(3): 649-659. doi: 10.1128/AAC.45.3.649-659.2001
    [12]
    Fischetti V A. Bacteriophage lysins as effective antibacterials[J]. Curr Opin Microbiol, 2008, 11(5): 393-400. doi: 10.1016/j.mib.2008.09.012
    [13]
    Young R. Bacteriophage lysis: Mechanism and regulation[J]. Microbiol Rev, 1992, 56(3): 430-481. doi: 10.1128/mr.56.3.430-481.1992
    [14]
    Gilmer D B, Schmitz J E, Euler C W, et al. Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2013, 57(6): 2743-2750. doi: 10.1128/AAC.02526-12
    [15]
    Loc-Carrillo C, Abedon S T. Pros and cons of phage therapy[J]. Bacteriophage, 2011, 1(2): 111-114. doi: 10.4161/bact.1.2.14590
    [16]
    Lu Y, Wang Y, Wang J, et al. Phage endolysin LysP108 showed promising antibacterial potential against methicillin-resistant Staphylococcus aureus[J]. Front Cell Infect Microbiol, 2021, 11: 668430. doi: 10.3389/fcimb.2021.668430
    [17]
    Fischetti V A, Nelson D, Schuch R. Reinventing phage therapy: Are the parts greater than the sum?[J]. Nat Biotechnol, 2006, 24(12): 1508-1511. doi: 10.1038/nbt1206-1508
    [18]
    Zhu Y, Hao W, Wang X, et al. Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug-resistant infections[J]. Med Res Rev, 2022, 42(4): 1377-1422.
    [19]
    Fischetti V A. Bacteriophage lytic enzymes: Novel anti-infectives[J]. Trends Microbiol, 2005, 13(10): 491-496. doi: 10.1016/j.tim.2005.08.007
    [20]
    Kortright K E, Chan B K, Koff J L, et al. Phage therapy: A renewed approach to combat antibiotic-resistant bacteria[J]. Cell Host Microbe, 2019, 25(2): 219-232. doi: 10.1016/j.chom.2019.01.014
    [21]
    Röhrig C, Huemer M, Lorgé D, et al. Targeting hidden pathogens: Cell-penetrating enzybiotics eradicate intracellular drug-resistant Staphylococcus aureus[J]. mBio, 2020, 11(2): e00209-e00220. doi: 10.1128/mbio.00209-20
    [22]
    Yılmaz Ç, Özcengiz G. Antibiotics: Pharmacokinetics, toxicity, resistance and multidrug efflux pumps[J]. Biochem Pharmacol, 2017, 133: 43-62.
    [23]
    Hatfull G F, Dedrick R M, Schooley R T. Phage therapy for antibiotic-resistant bacterial infections[J]. Annu Rev Med, 2022, 73: 197-211. doi: 10.1146/annurev-med-080219-122208
    [24]
    Górski A, Dąbrowska K, Międzybrodzki R, et al. Phages and immunomodulation[J]. Future Microbiol, 2017, 12(10): 905-914. doi: 10.2217/fmb-2017-0049
    [25]
    Oliveira H, São-José C, Azeredo J. Phage-derived peptidoglycan degrading enzymes: Challenges and future prospects for in vivo therapy[J]. Viruses, 2018, 10(6): 292. doi: 10.3390/v10060292
    [26]
    Oliveira H, Melo L D R, Santos S B, et al. Molecular aspects and comparative genomics of bacteriophage endolysins[J]. J Virol, 2013, 87(8): 4558-4570. doi: 10.1128/JVI.03277-12
    [27]
    Matamp N, Bhat S G. Phage endolysins as potential antimicrobials against multidrug resistant Vibrio alginolyticus and Vibrio parahaemolyticus: Current status of research and challenges ahead[J]. Microorganisms, 2019, 7(3): 84. doi: 10.3390/microorganisms7030084
    [28]
    Eugster M R, Haug M C, Huwiler S G, et al. The cell wall binding domain of Listeria bacteriophage endolysin PlyP35 recognizes terminal GlcNAc residues in cell wall teichoic acid[J]. Mol Microbiol, 2011, 81(6): 1419-1432. doi: 10.1111/j.1365-2958.2011.07774.x
    [29]
    Briers Y, Volckaert G, Cornelissen A, et al. Muralytic activity and modular structure of the endolysins of Pseudomonas aeruginosa bacteriophages φKZ and EL[J]. Mol Microbiol, 2007, 65(5): 1334-1344. doi: 10.1111/j.1365-2958.2007.05870.x
    [30]
    García P, García J, García E, et al. Modular organization of the lytic enzymes of Streptococcus pneumoniae and its bacteriophages[J]. Gene, 1990, 86(1): 81-88. doi: 10.1016/0378-1119(90)90116-9
    [31]
    Kong M, Na H, Ha N C, et al. LysPBC2, a novel endolysin harboring a Bacillus cereus spore binding domain[J]. Appl Environ Microbiol, 2019, 85(5): e02462-e02418. doi: 10.1128/aem.02462-18
    [32]
    Höltje J V, Mirelman D, Sharon N, et al. Novel type of murein transglycosylase in Escherichia coli[J]. J Bacteriol, 1975, 124(3): 1067-1076. doi: 10.1128/jb.124.3.1067-1076.1975
    [33]
    Rodríguez-Rubio L, Gerstmans H, Thorpe S, et al. DUF3380 domain from a Salmonella phage endolysin shows potent N-acetylmuramidase activity[J]. Appl Environ Microbiol, 2016, 82(16): 4975-4981. doi: 10.1128/AEM.00446-16
    [34]
    Thurber R V. Current insights into phage biodiversity and biogeography[J]. Curr Opin Microbiol, 2009, 12(5): 582-587. doi: 10.1016/j.mib.2009.08.008
    [35]
    Vázquez R, Gutiérrez D, Criel B, et al. Diversity, structure-function relationships and evolution of cell wall-binding domains of staphylococcal phage endolysins[J]. Int J Biol Macromol, 2025, 310: 143093. doi: 10.1016/j.ijbiomac.2025.143093
    [36]
    Wang I N, Smith D L, Young R. Holins: The protein clocks of bacteriophage infections[J]. Annu Rev Microbiol, 2000, 54: 799-825. doi: 10.1146/annurev.micro.54.1.799
    [37]
    Chamblee J S, Ramsey J, Chen Y, et al. Endolysin regulation in phage mu lysis[J]. mBio, 2022, 13(3): e00813-e00822. doi: 10.1128/mbio.00813-22
    [38]
    Abdelrahman F, Easwaran M, Daramola O I, et al. Phage-encoded endolysins[J]. Antibiotics, 2021, 10(2): 124. doi: 10.3390/antibiotics10020124
    [39]
    Taati Moghadam M, Mohebi S, Sheikhi R, et al. Phage and endolysin therapy against antibiotics resistant bacteria: From bench to bedside[J]. MedComm, 2025, 6(7): e70280. doi: 10.1002/mco2.70280
    [40]
    Haddad Kashani H, Schmelcher M, Sabzalipoor H, et al. Recombinant endolysins as potential therapeutics against antibiotic-resistant Staphylococcus aureus: Current status of research and novel delivery strategies[J]. Clin Microbiol Rev, 2018, 31: e00071-e00017.
    [41]
    Borysowski J, Weber-Dabrowska B, Górski A. Bacteriophage endolysins as a novel class of antibacterial agents[J]. Exp Biol Med, 2006, 231(4): 366-377. doi: 10.1177/153537020623100402
    [42]
    Nelson D, Loomis L, Fischetti V A. Prevention and elimination of upper respiratory colonization of mice by group a streptococci by using a bacteriophage lytic enzyme[J]. Proc Natl Acad Sci U S A, 2001, 98(7): 4107-4112. doi: 10.1073/pnas.061038398
    [43]
    Jun S Y, Jang I J, Yoon S, et al. Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers[J]. Antimicrob Agents Chemother, 2017, 61(6): e02629-e02616. doi: 10.1128/aac.02629-16
    [44]
    Jun S Y, Jung G M, Yoon S J, et al. Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient[J]. Antimicrob Agents Chemother, 2014, 58(4): 2084-2088. doi: 10.1128/AAC.02232-13
    [45]
    Jun S Y, Jung G M, Yoon S J, et al. Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period[J]. Clin Exp Pharmacol Physiol, 2016, 43(10): 1013-1016. doi: 10.1111/1440-1681.12613
    [46]
    Zhang L, Li D, Li X, et al. LysGH15 kills Staphylococcus aureus without being affected by the humoral immune response or inducing inflammation[J]. Sci Rep, 2016, 6: 29344. doi: 10.1038/srep29344
    [47]
    Gerstmans H, Criel B, Briers Y. Synthetic biology of modular endolysins[J]. Biotechnol Adv, 2018, 36(3): 624-640. doi: 10.1016/j.biotechadv.2017.12.009
    [48]
    Burgin D J, Liu R, Hsieh R C, et al. Investigational agents for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: Progress in clinical trials[J]. Expert Opin Investig Drugs, 2022, 31(3): 263-279. doi: 10.1080/13543784.2022.2040015
    [49]
    Fischetti V A. Novel method to control pathogenic bacteria on human mucous membranes[J]. Ann N Y Acad Sci, 2003, 987: 207-214. doi: 10.1111/j.1749-6632.2003.tb06050.x
    [50]
    Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: Potential impact on course of inflammation and outcome in sepsis and meningitis[J]. Clin Microbiol Rev, 2002, 15(1): 95-110. doi: 10.1128/CMR.15.1.95-110.2002
    [51]
    Schuch R, Lee H M, Schneider B C, et al. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus–induced murine bacteremia[J]. J Infect Dis, 2014, 209(9): 1469-1478. doi: 10.1093/infdis/jit637
    [52]
    Rashel M, Uchiyama J, Ujihara T, et al. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11[J]. J Infect Dis, 2007, 196(8): 1237-1247. doi: 10.1086/521305
    [53]
    Cheng M, Zhang Y, Li X, et al. Endolysin LysEF-P10 shows potential as an alternative treatment strategy for multidrug-resistant Enterococcus faecalis infections[J]. Sci Rep, 2017, 7: 10164. doi: 10.1038/s41598-017-10755-7
    [54]
    Loeffler J M, Djurkovic S, Fischetti V A. Phage lytic enzyme cpl-1 as a novel antimicrobial for pneumococcal bacteremia[J]. Infect Immun, 2003, 71(11): 6199-6204. doi: 10.1128/IAI.71.11.6199-6204.2003
    [55]
    Lai M J, Lin N T, Hu A, et al. Antibacterial activity of Acinetobacter baumannii phage ϕAB2 endolysin (LysAB2) against both Gram-positive and Gram-negative bacteria[J]. Appl Microbiol Biotechnol, 2011, 90(2): 529-539. doi: 10.1007/s00253-011-3104-y
    [56]
    Daniel A, Euler C, Collin M, et al. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-Resistant Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2010, 54(4): 1603-1612. doi: 10.1128/AAC.01625-09
    [57]
    李雪林, 杨小燕, 韩泽华, 等. 噬菌体联合抗生素疗法的协同作用机制及应用进展[J]. 昆明医科大学学报, 2025, 46(12): 1-8. doi: 10.12259/j.issn.2095-610X.S20251201
    [58]
    Harshitha N, Saha A, Mandal A, et al. Combination of endolysin LysK04 and cinnamaldehyde potentially inhibits Gram-negative pathogens via outer membrane disruption and peptidoglycan hydrolysis[J]. Microb Pathog, 2026, 211: 108262. doi: 10.1016/j.micpath.2025.108262
    [59]
    Kim N H, Park W B, Cho J E, et al. Effects of phage endolysin SAL200 combined with antibiotics on Staphylococcus aureus infection[J]. Antimicrob Agents Chemother, 2018, 62(10): e00731-e00718. doi: 10.1128/aac.00731-18
    [60]
    Thummeepak R, Kitti T, Kunthalert D, et al. Enhanced antibacterial activity of Acinetobacter baumannii bacteriophage ØABP-01 endolysin (LysABP-01) in combination with colistin[J]. Front Microbiol, 2016, 7: 1402. doi: 10.3389/fmicb.2016.01402
    [61]
    Kunz Coyne A J, Eshaya M, Bleick C, et al. Exploring synergistic and antagonistic interactions in phage-antibiotic combinations against ESKAPE pathogens[J]. Microbiol Spectr, 2024, 12(10): e00427-e00424.
    [62]
    Jo J, Myung H. Comparative combinatorial effects of endolysins LNT103 with ten conventional antibiotics against gram-negative bacterial pathogens[J]. J Microbiol Biotechnol, 2026, 36: e2601019. doi: 10.4014/jmb.2601.01019
    [63]
    Shannon R, Radford D R, Balamurugan S. Impacts of food matrix on bacteriophage and endolysin antimicrobial efficacy and performance[J]. Crit Rev Food Sci Nutr, 2020, 60(10): 1631-1640. doi: 10.1080/10408398.2019.1584874
    [64]
    Dörr T. Understanding tolerance to cell wall–active antibiotics[J]. Ann N Y Acad Sci, 2021, 1496(1): 35-58. doi: 10.1111/nyas.14541
    [65]
    Tamai E, Yoshida H, Sekiya H, et al. X-ray structure of a novel endolysin encoded by episomal phage phiSM101 of Clostridium perfringens[J]. Mol Microbiol, 2014, 92(2): 326-337.
    [66]
    Nariya H, Miyata S, Tamai E, et al. Identification and characterization of a putative endolysin encoded by episomal phage phiSM101 of Clostridium perfringens[J]. Appl Microbiol Biotechnol, 2011, 90(6): 1973-1979. doi: 10.1007/s00253-011-3253-z
    [67]
    Hoopes J T, Stark C J, Kim H A, et al. Use of a bacteriophage lysin, PlyC, as an enzyme disinfectant against Streptococcus equi[J]. Appl Environ Microbiol, 2009, 75(5): 1388-1394. doi: 10.1128/AEM.02195-08
    [68]
    Wang Y, Sun J H, Lu C P. Purified recombinant phage lysin LySMP: An extensive spectrum of lytic activity for swine streptococci[J]. Curr Microbiol, 2009, 58(6): 609-615. doi: 10.1007/s00284-009-9379-x
    [69]
    Schuch R, Nelson D, Fischetti V A. A bacteriolytic agent that detects and kills Bacillus anthracis[J]. Nature, 2002, 418(6900): 884-889. doi: 10.1038/nature01026
    [70]
    Chang Y, Kim M, Ryu S. Characterization of a novel endolysin LysSA11 and its utility as a potent biocontrol agent against Staphylococcus aureus on food and utensils[J]. Food Microbiol, 2017, 68: 112-120. doi: 10.1016/j.fm.2017.07.004
    [71]
    Lim J A, Shin H, Kang D H, et al. Characterization of endolysin from a Salmonella Typhimurium-infecting bacteriophage SPN1S[J]. Res Microbiol, 2012, 163(3): 233-241. doi: 10.1016/j.resmic.2012.01.002
    [72]
    Endersen L, Coffey A, Ross R P, et al. Characterisation of the antibacterial properties of a bacterial derived peptidoglycan hydrolase (LysCs4), active against C. sakazakii and other Gram-negative food-related pathogens[J]. Int J Food Microbiol, 2015, 215: 79-85. doi: 10.1016/j.ijfoodmicro.2015.08.007
    [73]
    Mayer M J, Gasson M J, Narbad A. Genomic sequence of bacteriophage ATCC 8074-B1 and activity of its endolysin and engineered variants against Clostridium sporogenes[J]. Appl Environ Microbiol, 2012, 78(10): 3685-3692. doi: 10.1128/AEM.07884-11
    [74]
    Son B, Yun J, Lim J A, et al. Characterization of LysB4, an endolysin from the Bacillus cereus-infecting bacteriophage B4[J]. BMC Microbiol, 2012, 12(1): 33. doi: 10.1186/1471-2180-12-33
    [75]
    Lai W C B, Chen X, Ho M K Y, et al. Bacteriophage-derived endolysins to target gram-negative bacteria[J]. Int J Pharm, 2020, 589: 119833. doi: 10.1016/j.ijpharm.2020.119833
    [76]
    Murray E, Draper L A, Ross R P, et al. The advantages and challenges of using endolysins in a clinical setting[J]. Viruses, 2021, 13(4): 680. doi: 10.3390/v13040680
    [77]
    Bruno B J, Miller G D, Lim C S. Basics and recent advances in peptide and protein drug delivery[J]. Ther Deliv, 2013, 4(11): 1443-1467. doi: 10.4155/tde.13.104
    [78]
    Khan F M, Gondil V S, Li C, et al. A novel Acinetobacter baumannii bacteriophage endolysin LysAB54 with high antibacterial activity against multiple gram-negative microbes[J]. Front Cell Infect Microbiol, 2021, 11: 637313. doi: 10.3389/fcimb.2021.637313
    [79]
    Yang H, Wang M, Yu J, et al. Antibacterial activity of a novel peptide-modified lysin against Acinetobacter baumannii and Pseudomonas aeruginosa[J]. Front Microbiol, 2015, 6: 1471. doi: 10.3389/fmicb.2015.01471
    • Relative Articles(20)

  • Relative Articles

    [1] Zehua HAN, Xiaoyan YANG, Yuliang CHEN, Xuelin LI, Rongyu YANG, Yingying XIANG. Research Progress on Bacteriophage Prevention and Treatment of Dental Caries. Journal of Kunming Medical University,  doi: 10.12259/j.issn.2095-610X.S20260117
    [2] Zehua HAN, Xiaoyan YANG, Yuliang CHEN, Xuelin LI, Rongyu YANG, Yingying XIANG. Research Progress on Bacteriophage Prevention and Treatment of Dental Caries. Journal of Kunming Medical University,
    [3] Xuelin LI, Xiaoyan YANG, Zehua HAN, Yuliang CHEN, Xingyuan XU, Chunyan ZHANG, Yingying XIANG. Synergistic Mechanisms and Applications of Phage-antibiotic Combination Therapy. Journal of Kunming Medical University,  doi: 10.12259/j.issn.2095-610X.S20251201
    [4] Hao HUANG, Xuelin LI, Zehua HAN, Lin CHANG, Pengfei ZHU, Yingying XIANG. Application of Bacteriophages in Common Infectious Diseases of the Oral Cavity. Journal of Kunming Medical University,  doi: 10.12259/j.issn.2095-610X.S20250122
    [5] Yahong SUN, Xiaoyu YANG, Rui ZHENG. Progress and Challenges in the Study of Bacteriophage Therapy for Carbapenem-Resistant Klebsiella Pneumoniae Infection. Journal of Kunming Medical University,  doi: 10.12259/j.issn.2095-610X.S20250621
    [6] Jie LI, Yuan HE, Chunyan WU, Bin SHAN, Rui ZHENG, Zhifu GUAN, Baojun REN, Chunxia SHI, Youquan ZHOU, Hanyu LIU, Mi ZHANG, Yanming KANG, Guibo SONG. Distribution and Drug Resistance Analysis of Bacteria in Sterile Body Fluids in Yunnan from 2017 to 2021. Journal of Kunming Medical University,  doi: 10.12259/j.issn.2095-610X.S20230309
    [7] Jinyi GU, Deyao DENG, Wenli YUAN, Qiuping YANG, Jianmei SONG, Yanjun SHEN, Yuanyuan GUO, Hongyun XU. Clinical Distribution and Drug Resistance Analysis of Acineto Bacterbaumannii from 2014 to 2020. Journal of Kunming Medical University,  doi: 10.12259/j.issn.2095-610X.S20220504
    [8] Rongyu YANG, Fei SONG, Yunlin WEI, Xianghong YANG, Kaiwen Duan, Yingying XIANG. Effects of Different Accumulation Culture Methods on the Titer of Phage PEf771. Journal of Kunming Medical University,  doi: 10.12259/j.issn.2095-610X.S20220218
    [9] Pu-mei CUI, Tai-fang CHEN, Chao CHEN, Yong-mei LIANG, Yue XU. Correlation Analysis of Antimicrobial Use and Common Bacterial Resistance in a Hospital in Yunnan From 2016 to 2019. Journal of Kunming Medical University,  doi: 10.12259/j.issn.2095-610X.S20211127
    [10] Xiang Ying Ying , Song Fei , Yang Xiang Hong , Zhou Jing , Yu Hong Bin , Wei Yun Lin , Ji Xiu Ling . . Journal of Kunming Medical University,
    [11] Gong Rong , Sun Wei , Xu Cong Qiong , Liu Lin , Wang Juan , Jin Zhen . . Journal of Kunming Medical University,
    [12] Wang Yang . Investigation of Resistance and Genotypes of Extended-spectrum β-lactamases Produced by Pseudomonas aeruginosa in Kunming. Journal of Kunming Medical University,
    [13] Ma Jin Hua . Distribution and Antimicrobial Susceptibility of Anaerobic Bacteria in Periodontal Pocket of 84 Patients with Chronic Periodontitis. Journal of Kunming Medical University,
    [14] Jing Xiao Jie . . Journal of Kunming Medical University,
    [15] Zhang Yong Chun . . Journal of Kunming Medical University,
    [16] Li Xiao Fei . . Journal of Kunming Medical University,
    [17] Wu Gao Li . . Journal of Kunming Medical University,
    [18] Zhou Shi Qiao . . Journal of Kunming Medical University,
    [19] Chen Rui Chun . . Journal of Kunming Medical University,
    [20] . . Journal of Kunming Medical University,
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (60) PDF downloads(15) Cited by()
    Proportional views
    Related

    Copyright © 《昆明医科大学学报》编辑部  滇ICP备00000000号-0

    Publishing: 昆明医科大学学报编辑部

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return